The Perioperative Management of Antithrombotic Therapies Using Enoxaparin.
10.3346/jkms.2017.32.6.942
- Author:
Hun Gyu HWANG
1
;
So My KOO
;
Soo Taek UH
;
Yang Ki KIM
Author Information
1. Depertment of Internal Medicine, Soonchunhyang University Gumi Hospital, Gumi, Korea.
- Publication Type:Original Article
- Keywords:
Thromboembolism;
Anticoagulation;
Vitamin K Antagonist;
Bridging;
Low-Molecular-Weight Heparin
- MeSH:
Anticoagulants;
Atrial Fibrillation;
Enoxaparin*;
Hemorrhage;
Hemostasis;
Heparin, Low-Molecular-Weight;
Humans;
Incidence;
Injections, Subcutaneous;
Korea;
Male;
Minor Surgical Procedures;
Mortality;
Retrospective Studies;
Thromboembolism;
Venous Thromboembolism;
Warfarin
- From:Journal of Korean Medical Science
2017;32(6):942-947
- CountryRepublic of Korea
- Language:English
-
Abstract:
Oral anticoagulant therapy is frequently and increasingly prescribed for patients at risk of arterial or venous thromboembolism (VTE). Although elective surgical or invasive procedures have necessitated temporary interruption of anticoagulants, managing these patients has been performed empirically and been poorly investigated. This study was designed to evaluate the adequacy of perioperative anticoagulation using enoxaparin. This was a retrospective, single-center study that evaluated the efficacy and safety of therapeutic-dose enoxaparin for bridging therapy in patients on long-term warfarin at Soonchunhyang University Hospital in Korea between August 2009 and July 2011. Warfarin was discontinued 5 days before surgery, and enoxaparin was administered twice daily by subcutaneous injection at a dose of 1 mg per kg from 3 days before the procedure to the last dose 24 hours before the procedure. Anticoagulation was restarted if proper hemostasis had been confirmed. There were 49 patients, of whom 25 (51%) were men, and the mean age was 63 years. Thirty-four (69%) received warfarin therapy for VTE, and 9 (18%) for atrial fibrillation. Twenty-nine patients (59%) underwent major surgery and 20 (41%) minor surgery. The mean postoperative duration of enoxaparin was 4 days. No patients had thromboembolic complications through 30 days after the procedure. The overall 30-day mortality rate was 0%. In conclusion, our findings demonstrate that bridging therapy with therapeutic-dose enoxaparin is feasible and associated with a low incidence of major bleeding and no thromboembolic complications. However, the optimal approach to managing patients perioperatively is uncertain and requires further evaluation.
